Balyasny Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
Sell
-70,502
Closed -$108K 1947
2025
Q1
$108K Buy
+70,502
New +$108K ﹤0.01% 1902
2024
Q3
Sell
-13,910
Closed -$15.3K 1909
2024
Q2
$15.3K Buy
+13,910
New +$15.3K ﹤0.01% 1846
2023
Q4
Sell
-10,511
Closed -$72K 1868
2023
Q3
$72K Buy
+10,511
New +$72K ﹤0.01% 1661
2023
Q1
Sell
-20,503
Closed -$323K 2144
2022
Q4
$323K Sell
20,503
-85,644
-81% -$1.35M ﹤0.01% 1542
2022
Q3
$1.67M Buy
+106,147
New +$1.67M 0.01% 1208
2022
Q2
Sell
-209,636
Closed -$3.61M 2245
2022
Q1
$3.61M Sell
209,636
-256,764
-55% -$4.43M 0.01% 847
2021
Q4
$6.78M Buy
466,400
+304,557
+188% +$4.43M 0.02% 630
2021
Q3
$2.91M Buy
161,843
+7,423
+5% +$134K 0.01% 830
2021
Q2
$2.71M Buy
+154,420
New +$2.71M 0.01% 818
2019
Q1
Sell
-315,167
Closed -$2.33M 1266
2018
Q4
$2.33M Sell
315,167
-274,833
-47% -$2.03M 0.02% 601
2018
Q3
$8.57M Sell
590,000
-110,111
-16% -$1.6M 0.04% 437
2018
Q2
$14M Sell
700,111
-285,865
-29% -$5.71M 0.06% 343
2018
Q1
$17.3M Buy
985,976
+58,059
+6% +$1.02M 0.07% 318
2017
Q4
$22.9M Buy
927,917
+461,340
+99% +$11.4M 0.07% 325
2017
Q3
$12M Buy
466,577
+46,577
+11% +$1.2M 0.05% 379
2017
Q2
$11.4M Buy
420,000
+21,250
+5% +$576K 0.05% 427
2017
Q1
$11.9M Buy
398,750
+48,750
+14% +$1.45M 0.06% 377
2016
Q4
$9.5M Buy
350,000
+250,798
+253% +$6.81M 0.05% 400
2016
Q3
$2.54M Buy
+99,202
New +$2.54M 0.01% 585